Lung transplantation (TxP) is now a well-established treatment option for irreversible end-stage chronic respiratory failure in selected patients. While survival after TxP has steadily increased over time, the medium- and long-term morbidity and functional prognosis of the graft remain linked to complications such as acute cellular/humoral rejection (AR) and chronic rejection, the incidence of which is still very high. Episodes of rejection sometimes go undetected, because they are not clinically informative or are too closely associated with other graft-related events (infectious, mechanical, metabolic, etc.).
The gold standard for diagnosing rejection is based on histopathological criteria, using lung samples, which are an invasive and risky procedure. Innovative, non-invasive, less costly and reproducible tools for screening and/or diagnosing rejection would be highly desirable. Research focusing on non-invasive biomarkers is already underway in areas such as oncology and prenatal diagnosis, but is in its early stages in organ transplantation, particularly after kidney transplants. This Research Topic aims to collect research on non-invasive biomarkers and lung transplantation.
Special attention will be given to studies concerning non-invasive biomarkers such as cfDNA, dd-cfDNA, circulating nucleic acids, biochemical biomarkers, DSA, etc. These studies may include biomarkers in blood as well as in other biological or non-biological fluids (graft preservation fluid, etc.).
Keywords:
Biomarkers, Lung Transplantation, Rejection, Acute Rejection, Chronic Rejection, Humoral Rejection, Cellular Rejection
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Lung transplantation (TxP) is now a well-established treatment option for irreversible end-stage chronic respiratory failure in selected patients. While survival after TxP has steadily increased over time, the medium- and long-term morbidity and functional prognosis of the graft remain linked to complications such as acute cellular/humoral rejection (AR) and chronic rejection, the incidence of which is still very high. Episodes of rejection sometimes go undetected, because they are not clinically informative or are too closely associated with other graft-related events (infectious, mechanical, metabolic, etc.).
The gold standard for diagnosing rejection is based on histopathological criteria, using lung samples, which are an invasive and risky procedure. Innovative, non-invasive, less costly and reproducible tools for screening and/or diagnosing rejection would be highly desirable. Research focusing on non-invasive biomarkers is already underway in areas such as oncology and prenatal diagnosis, but is in its early stages in organ transplantation, particularly after kidney transplants. This Research Topic aims to collect research on non-invasive biomarkers and lung transplantation.
Special attention will be given to studies concerning non-invasive biomarkers such as cfDNA, dd-cfDNA, circulating nucleic acids, biochemical biomarkers, DSA, etc. These studies may include biomarkers in blood as well as in other biological or non-biological fluids (graft preservation fluid, etc.).
Keywords:
Biomarkers, Lung Transplantation, Rejection, Acute Rejection, Chronic Rejection, Humoral Rejection, Cellular Rejection
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.